Wegovy and HRT: what you need to know before combining them

Does Wegovy affect how HRT is absorbed?

Wegovy works partly by slowing the rate at which the stomach empties. That is the mechanism behind much of its appetite-reducing effect. The same mechanism can delay the absorption of other medicines that pass through the gut, including oral HRT tablets. A slower transit time does not necessarily make oral HRT ineffective, but it does mean the pharmacokinetics (essentially, the timing and peak of absorption) are less predictable.

NHS England's guidance on weight-management injections explicitly advises considering transdermal HRT preparations (patches, gels or sprays applied to the skin) for women on tirzepatide, because they bypass the gut entirely. The biological reason is identical for semaglutide: a medicine delivered through the skin does not depend on gastric emptying at all, so its absorption is not affected by Wegovy in the same way. If you are already established on oral HRT and doing well, that does not necessarily mean you need to switch — but it is a conversation worth having with the prescriber who manages your HRT before you start weight-management treatment. You can read more about taking Wegovy and HRT together on a dedicated page.

There is limited direct head-to-head trial data on semaglutide specifically and oral HRT absorption in the same participants, so guidance is based on pharmacological reasoning and the broader evidence on GLP-1 medicines and oral drug absorption. The NHS recommends discussing this with your healthcare team rather than making unilateral changes.

Does HRT affect whether Wegovy works for weight loss?

This question comes up regularly, and the short answer is: HRT is not believed to undermine the weight-loss effect of semaglutide. The clinical trials for Wegovy included women across a range of ages, and there is no established evidence that concurrent HRT blunts the treatment's efficacy. Many women find that managing menopausal symptoms well (through HRT, lifestyle or both) actually makes it easier to sustain the behaviour changes that support weight loss, including sleep and activity levels.

What is true is that menopause itself is associated with changes in body composition, including a tendency to accumulate abdominal fat, that can make weight management harder. Wegovy addresses appetite and satiety centrally; it does not interact with oestrogen or progesterone pathways in a way that would reduce its clinical effect. The STEP 1 trial, published in the New England Journal of Medicine, reported an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose, and that evidence base informs the current UK licence. There is no subgroup analysis specifically isolating HRT users, but nothing in the pharmacology suggests a clinically meaningful interaction in that direction.

If you want a broader picture of the treatment itself, our Wegovy overview covers the licensed indication, dosing pathway and what to expect.

Which HRT formulation is likely to work best alongside semaglutide?

Transdermal preparations (patches, gels and sprays) are generally considered the more predictable choice when gastric emptying may be altered. They deliver oestrogen directly through the skin into the bloodstream, sidestepping the digestive system entirely. Progesterone-containing components of HRT (such as micronised progesterone capsules taken at night) are taken orally and, strictly speaking, could be subject to the same absorption variability; your prescriber may want to factor this in.

Vaginal preparations for local symptoms (rings, pessaries, creams) are minimally absorbed systemically and are not relevant to this absorption question at all.

The practical upshot is that if you and your GP or menopause specialist are considering starting HRT while you are on Wegovy (or vice versa) a frank conversation about your existing formulation is sensible. The NHS England guidance on weight-management injections covers this point in its wraparound care section, and it is worth taking a copy to your appointment if your GP is less familiar with the interaction. For questions specific to whether semaglutide changes the behaviour of your current HRT, the page on whether Wegovy affects HRT goes into further detail.

What should you tell your prescriber, and when?

Before any prescriber can assess you for Wegovy, they need the full picture of what you are already taking. That includes HRT in all its forms, oral tablets, patches, gels, intrauterine systems and vaginal preparations. It also includes any other regular medicines, including those prescribed for other conditions. The most common questions our prescribers receive include exactly this one: do I need to tell you about my HRT? Yes, always.

At nume, every consultation is personally reviewed by a GPhC-registered Independent Prescriber, a real clinician reads your answers. If you are on HRT, that will be part of what they consider when they assess your suitability and, if appropriate, discuss which formulation choice sits best with your situation. You will not be left to piece that together yourself. Our clinical team takes a whole-picture approach to every review.

One practical note: Wegovy arrives in plain, unbranded packaging via DPD with a tracking link, so there is nothing to announce on the doorstep. What matters is that everything you need to know about storing and using your pen is in the patient information leaflet inside, and your prescriber will already have been through your medication list before it is dispatched. If you are ready to talk through your options, you can start your free consultation and a prescriber will review your submission the same day.

If you are also curious about other aspects of Wegovy and your health, the pages on Wegovy and skin changes, B12 and Wegovy, and how Wegovy interacts with MS cover questions that often come up alongside HRT queries.